+91-8668442535

Anaplastic Lymphoma Kinase Inhibitors Market By Molecule (Crizotinib, Ceritinib and Alectinib Hydrochloride) - Growth, Future Prospects & Competitive Analysis, 2019 – 2027

Industry Outlook

The anaplastic lymphoma kinase (ALK) inhibitors market is set to reach from US$ 1,496.4 Mn in 2018 to 8,329.1 Mn by 2027 keen to demonstrate exuberating growth at a compounded annual growth rate (CAGR) of 21.2% during the forecast period from 2019 to 2027. Lung cancer is the second most occurring type of cancer in both men and women population worldwide. Increased consumption of tobacco, unhealthy lifestyle and stress are the major risk factor responsible for the occurrence of lung cancer. A strong drug pipeline of second and third generation ALK inhibitors being currently studied in various stages of clinical trials are being developed specifically for the treatment of non small cell lung cancer (NSCLC).

Market Synopsis

Anaplastic Lymphoma Kinase Inhibitors Market 

Get a sample copy for more information

"Excellent pharmacodynamic and pharmacokinetic properties drive the market growth of first generation ALK inhibitors"

Non small cell lung cancer (NSCLC) is the most common type of lung cancer occurring throughout the globe. The prognosis of the NSCLC is difficult and its initial screening is rather poor which significantly increases the requirement for development of targeted drug therapy for its treatment. FDA has approved only 2 drugs specifically for the treatment of NSCLC In the present scenario first generation ALK inhibitor Crizotinib is spearheading the molecule segment for anaplastic lymphoma kinase inhibitors market. It is basically an aminopyridine and piperidine derivative which selectively inhibits receptor tyrosine kinase and the ALK fusion proteins during the treatment of NSCLC. It has the potency to inhibit tumor cell growth. Alectinib hydrochloride is another first line ALK inhibitor which effectively inhibits wild type ALK point mutant variants and disrupts the tumor cell growth associated with advanced stage NSCLC.  Hence, excellent pharmacodynamic and pharmacokinetic properties together drive the market growth for first generation ALK inhibitors.

Anaplastic Lymphoma Kinase Inhibitors Market

Get a sample copy for more information

"Rising prevalence of lung cancer and affordable reimbursement scenario together drive the market growth in North America region"

Representing a share of 36.2% North America is currently leading the regional segment for anaplastic lymphoma kinase (ALK) inhibitors market. According to the research findings of American Society of Clinical Oncology (ASCO), in 2019, approximately 228,150 U.S. citizens have been reported to be suffering with lung cancer with a high prevalence rate in African American people. Affordable reimbursement scenario pertaining to the treatment of non small cell lung cancer drives the market growth ALK inhibitors in North America region. Europe is in the second place with 29.8% market share primarily due to huge prevalence rate of lung cancer in the European Union which is 54 per 100,000 people as brought forward by the 2018 statistical report of European Commission. Supportive regulatory environment provided by the European Medical Agency to expedite the clinical trials pertaining to second and third generation anaplastic lymphoma kinase inhibitors for the treatment of non small cell lung cancer  (NSCLC). Asia Pacific presently accounts for 15.5% market share and is keen to register outstanding growth during the forecast period on account of significant rise in tobacco consumption, thereby promoting the proliferation of NSCLC and developing healthcare infrastructure.

Anaplastic Lymphoma Kinase Inhibitors Market

Get a sample copy for more information

Historical & Forecast Period

This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market is segmented by molecule and by geography. 

ATTRIBUTE DETAILS
Research Period  2017-2027
Base Year 2018
Forecast Period  2019-2027
Historical Year  2017
Unit  USD Million
Segmentation

 By Molecule (2017–2027; US$ Mn)
 • Crizotinib
 • Ceritinib
 • Alectinib Hydrochloride

 Geography Segment (2017–2027; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of APAC)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of Middle East and Africa)

Biopharmaceutical companies actively seeking to create a strong foothold in the anaplastic lymphoma kinase inhibitors market are Betta Pharmaceutcials Co., Ltd., Crtierium, Inc., F.Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG., Oncoethix GmbH, Pfizer, Inc., Takeda Pharmaceutical Co., Ltd., Xcovery Holding Company, LLC and Tesaro, Inc.

Key questions answered in this report

  • Which biopharmaceutical companies are engaged in the development of ALK inhibitors for the treatment of NSCLC?
  • What are the inorganic and organic market growth strategies adopted for the market assessment of anaplastic lymphoma kinase inhibitors market?
  • What is the disease etiology associated with NSCLC?
  • Why are the first line ALK inhibitors employed selectively for the treatment of NSCLC?
  • What is the prevalence rate of lung cancer in developing nation of Asia Pacific and Latin America regional segment?
Choose License Type
Budget Buying
Executive Summary - Brief Global Market Size - Current & Forecast
Regional Market Size - North America
Country Market Size - US
Company Profile – 1
Trusted By
Godaddy
Published Date:  Jun 2019
Category:  Pharmaceuticals
Report ID:   59740
Report Format:   PDF
Pages:   120
Rating:    4.4 (49)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support